MEETING MINUTES OF THE CENTERS FOR MEDICARE AND MEDICAID SERVICES MEDICARE EVIDENCE DEVELOPMENT & COVERAGE ADVISORY COMMITTEE

July 22, 2020

Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, Maryland

Medicare Evidence Development & Coverage Advisory Committee

July 22, 2020

Attendees (Remotely)

Committee Chair Peter Bach, MD, MAPP

Committee Vice-Chair Joseph Ross, MD, MHS

MedCAC Members

Timothy J.Barreiro, DO, MPH, FCCP, FACOI
Anita Fernander, PhD, ABPBC
Gregory Joseph Dehmer, MD
Michael J. Fisch, MD, MPH, FACP, FAAHPM
Melissa M. Garrido, PhD, BS
Kim Kuebler, NP, APRN, ANP-BC
Greg Manship, DBe, Mdiv, MA
Joy Melnikow, MD, MPH
Marcel Salive, MD, MPH

CMS LiaisonJoseph Chin, MD

Industry Representative

Laura Mauri, MD

Guest Panel Members
Gerard J. Criner, MD, FACP, FACCP
Peter C.Gay, MD
Neil MacIntyre, MD

Invited Guest Speakers John M. Coleman III, MD Michael E. Wilson, MD

MEDCAC Coordinator Tara Hall

Wednesday, July 22, 2020, 8:03 a.m. EDT

The Medicare Evidence Development & Coverage Advisory Committee met virtually via Cisco WebEx on July 22, 2020, to evaluate the state of the evidence on home use of Noninvasive Positive Pressure Ventilation (NIPPV) in patients with chronic respiratory failure consequent to Chronic Obstructive Pulmonary Disease (COPD).

The meeting began with a reading of a conflict of interest statement, welcoming remarks, and an introduction of the Committee.

<u>CMS Presentation.</u> A CMS representative presented information summarizing the current national coverage decision for durable medical equipment that covers ventilators for neuromuscular disease, thoracic restrictive disease and chronic respiratory failure, and also commented on current clinical practice. She then presented the voting questions for the panel.

<u>Presentations by Invited Guest Speakers.</u> The panel heard presentations from the invited guest speakers. Dr. Wilson presented the results of the portion of a systematic review conducted by the Mayo Clinic Evidence-Based Practice Center pertaining to NIPPV on patients with COPD. Dr. Coleman spoke about the historic and current clinical role of NIPPV in the treatment COPD.

<u>Scheduled Public Comments.</u> The panel heard from six scheduled speakers, including society and industry representatives. These speakers informed the committee of current guidelines as well as ones under development, and commented on current clinical practice regarding utilization of NIPPV.

<u>Open Public Comments.</u> One member of the general public addressed the panel, representing a coalition of the seven leading home oxygen and sleep therapy providers and manufacturing companies.

<u>Questions to Presenters.</u> The panel participated in a lengthy discussion and question and answer session with all of the presenters, which is recorded in the transcript.

<u>Initial Open Panel Discussion, Formal Remarks and Voting Questions.</u> The panel conducted an in depth discussion of the issues raised, before turning its attention to the voting questions. During the voting, each panelist announced his or her vote, and provided reasoning for the vote. For those questions receiving a mean vote of intermediate confidence (2.5) or greater, the discussion questions were also addressed.

<u>Final Open Panel Discussion.</u> At the conclusion of voting and discussion questions, each panel member was given the opportunity to give final comments on topics covered, including next steps to be taken by CMS and the professional community.

<u>Closing Remarks.</u> Dr. Chin and Dr. Bach extended thanks to the panelists, presenters and public for participating in the meeting.

Adjournment. The meeting adjourned at 3:43 p.m. EDT.

I certify that I attended the meeting of the Medicare Evidence Development and Coverage Advisory Committee on July 22, 2020, and that these minutes accurately reflect what transpired.

Tara Hall

Tara Hall

MEDCAC Coordinator, CMS

I approve the minutes of this meeting

as recorded in this summary.

Peter Bach, MD, MAPP

MEDCAC Chair